细胞外信号调节激酶-2在结肠癌中的表达及临床意义

Expression and clinical significance of extracellular signal-regulated kinase-2 in colon cancer

目的研究细胞外信号调节激酶-2（ERK-2）在结肠癌组织中的表达及临床意义。方法选取山东省临朐县人民医院2008年1月~2010年12月经手术病理证实的结肠癌患者79例,采用免疫组化链霉菌抗生物素蛋白-过氧化酶（streptavidin-peroxidase,SP）法检测正常结肠组织、癌旁组织和结肠癌组织中ERK-2蛋白阳性表达情况;分析ERK-2蛋白表达与结肠癌临床病理特征及预后的关系。结果①结肠癌组织中ERK-2蛋白阳性表达率[75.9%（60/79）]高于癌旁组织[51.9%（41/79）]及正常组织[13.9%（11/79）],差异均有统计学意义（P〈0.05或P〈0.01）。②ERK-2蛋白阳性表达率在不同年龄（〈60岁、≥60岁）[77.5%（31/40）、74.4%（29/39）]、性别（男/女）[70.7%（29/41）、68.4%（26/38）]、Dukes分期（A、B、C、D期）[73.3%（11/15）、76.7%（23/30）、71.4%（10/14）、70.0%（14/20）]、癌胚抗原水平（〈5μg/L、≥5μg/L）[68.2%（15/22）、64.9%（37/57）]因素间进行比较,差异均无统计学意义（P〉0.05）;ERK-2蛋白阳性表达率在不同分化程度（高、中分化/低分化）[82.8%（48/58）、57.1%（12/21）]、浸润深度（未穿透肌层/浆膜或浆膜外）[46.2%（6/13）、72.7%（48/66）]和淋巴结转移（阳性/阴性）[76.5%（26/34）、53.3%（24/45）]因素间比较,差异有统计学意义（P〈0.05）。③ERK-2蛋白阳性表达患者12个月生存率（58.2%）与ERK-2蛋白阴性表达患者（60.4%）比较,差异无统计学意义（P〉0.05）;ERK-2蛋白阳性表达患者24个月生存率（38.7%）低于ERK-2蛋白阴性表达患者（58.6%）,差异有统计学意义（P〈0.05）。结论 ERK-2蛋白阳性表达与结肠癌多种临床病理因素有关,检测ERK-2蛋白对结肠癌的诊疗有一定意义。

Objective To investigate the expression and clinical significance of extracellular signal-regulated kinase-2 in colon cancer. Methods 79 patients with colon cancer confirmed by surgical pathology in People＇s Hospital of Linqu County from January 2008 to December 2010 were selected. Positive expression of ERK-2 protein in normal colon tissue, para-carcinoma tissue and colon cancer tissue were detected by immunohistochemical streptavidin-peroxidase （SP）. Relationships between ERK-2 protein expression and clinicopathological characteristics, prognosis of colon cancer were analyzed. Results ①Positive expression rate of ERK-2 protein in colon cancer tissue [75.9% （60/79）] was higher than that in para-carcinoma tissue [51.9% （41/79）] and normal colon tissue [13.9% （11/79）], the differences were statistically significant （P 〈 0.05 or P 〈 0.01）.②The ERK-2 protein positive expression rates in patients with different ages （〈60 years, ≥60 years） [77.5% （31/40）, 74.4% （29/39）], gender （male/female） [70.7% （29/41）, 68.4% （25/38）], Dukes stages （A, B, C, D） [73.3% （11/15）, 76.7% （23/30）, 71.4% （10/14）, 70.0% （14/20）], CEA levels （〈5 μg/L,≥5 μg/L） [68.2% （15/22）, 64.9% （37/57）] were not statistically significant （P 〉 0.05）; the ERK-2 protein positive expression rates in patients with different elements of differentiated degrees （high, moderately differentiated/low differentiated） [82.8% （48/58）, 57.1% （12/21）], depth of invasion （inside the muscularis/serous or serosa outside） [46.2% （6/13）, 72.7% （48/66）], lymphatic metastasis （positive/negative） [76.5% （26/34）, 53.3% （24/45）] were statistically significant （P 〈 0.05）.③The difference of 12 months survival rate between patients with ERK-2 protein positive expression （58.2%） and patients with ERK-2 protein negative expression （60.4%） was not statistically significant （P 〉 0.05）; 24 months survival rate in patients with ERK-2 protein positive expression （38.7%） was lower than those in patients with ERK-2 protein negative expression （58.6%）, the difference was statistically significant （P 〈 0.05）. Conclusion ERK-2 protein positive expression has relationship with variety of clinical pathological factors, ERK-2 protein detection has significance to diagnosis and treatment of colon cancer.